Publications by authors named "A Calleri"
Interleukin-1 Inhibition in Alcohol-associated Hepatitis: Are We Hitting the Right Target?
Clin Gastroenterol Hepatol
October 2024
Article Synopsis
- The study investigates a chemotherapy-free treatment combining atezolizumab, venetoclax, and obinutuzumab for patients with diffuse large B-cell lymphoma variant of Richter transformation, which is known for being difficult to treat and having a poor prognosis.
- It was a phase 2, multicenter trial involving 15 hospitals across Italy and Switzerland, targeting patients with a specific type of cancer transformation after certain prior conditions.
- The primary goal was to achieve an overall response rate of at least 67% by day 21 of cycle 6, with the study being registered under ClinicalTrials.gov, NCT04082897, and completed by October 2022.*
Extracellular vesicles (EVs) are emerging as a promising field of research in liver disease. EVs are small, membrane-bound vesicles that contain various bioactive molecules, such as proteins, lipids, and nucleic acids and are involved in intercellular communication. They have been implicated in numerous physiological and pathological processes, including immune modulation and tissue repair, which make their use appealing in liver transplantation (LT).
View Article and Find Full Text PDFRenal damage in Hepatorenal Syndrome: A still unsolved issue.
Clin Res Hepatol Gastroenterol
August 2023
Acute kidney injury (AKI) is a common complication of cirrhosis, burdened by high morbidity and mortality rates and progression to chronic kidney disease. Hepatorenal syndrome (HRS) is a peculiar type of functional AKI observed in cirrhotic patients with ascites. HRS diagnosis is still clinical, once pre-renal azotemia and intrinsic kidney damage have been excluded by applying well-established and internationally adopted criteria.
View Article and Find Full Text PDF